Clinical outcomes of surgical management for primary gastrointestinal diffuse large B-cell lymphoma: At a single institution experience
- Author:
Sung Woo JANG
1
;
Dae Ro LIM
;
Jung Kul KUK
;
Taehyung KIM
;
Eung Jin SHIN
Author Information
- Publication Type:Original Article
- Keywords: Lymphoma; Diffuse large B-cell lymphoma; Gastrointestinal tract; Surgery
- MeSH: Abdominal Pain; B-Lymphocytes; Cecum; Cyclophosphamide; Disease-Free Survival; Drug Therapy; Emergencies; Follow-Up Studies; Gastrointestinal Tract; Humans; Ileum; Intussusception; Lymphoma; Lymphoma, B-Cell; Prednisolone; Prognosis; Retrospective Studies; Rituximab; Stomach; Survival Rate; Vincristine
- From: Korean Journal of Clinical Oncology 2017;13(2):75-82
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The study aimed to analyze peri/postoperative outcomes and long-term oncologic outcomes after surgical management for primary gastrointestinal diffuse large B-cell lymphoma (DLBL).METHODS: Between January 2001 and December 2013, 19 patients who underwent surgery for primary gastrointestinal DLBL were retrieved from a retrospective database.RESULTS: With a median follow up of 49.2 months, the most common tumor locations were the terminal ileum and cecum (n=14, 73.7%) and stomach (n=4, 21.1%). The most common clinical symptoms were abdominal pain (n=15, 78.9%) and intussusceptions (n=5, 26.3%). None of the patients had B symptoms. Emergency surgery was undertaken in 36.8% (n=7) of the patients. Mean mass size was 8.4 cm; 4 patients (21.1%) had a bulky mass (>10 cm). The International Prognostic Index (IPI) scores were low (n=11, 57.9%), low-intermittent (n=7, 36.8%), and high-intermittent (n=1, 5.3%). Patients' staging was IE (n=9, 47.4%), IIE (n=8, 42.1%), and IVE (n=2, 10.5%) based on the Ann Arbor staging system, and I (n=2, 10.5%), II1 (n=5, 26.4%), IIE (n=10, 52.6%), and IV (n=2, 10.5%) based on the Lugano staging system. B-lymphocyte antigen CD20 was positive in most patients (n=17, 89.5%) and Ki-67 was high (>70%) in 12 patients (63.2%). Two types of chemotherapy were administered: cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone (n=5, 26.3%), rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone (n=13, 68.4%). The 5-year disease-free survival rate was 94.4% and the 5-year overall survival rate was 89.5%.CONCLUSION: Surgery for primary gastrointestinal DLBL is feasible and acceptable. Low staging of primary gastrointestinal DLBL has good prognosis.
